SUMMARY
Poor postoperative analgesia contributes to morbidity 1 . It is widely believed that postoperative pain is poorly managed 2 , indeed a working party of the National Health and Medical Research Council described pain management in Australia as "islands of enlightenment in a sea of misery" 3 . However, the management of postoperative pain has undergone significant advances in recent years. The advantages of patient-controlled analgesia (PCA) and epidural infusions have been well documented and have received widespread acceptance from patients, medical and nursing staff. Nevertheless there are some situations where these techniques may not be appropriate. Such patients are typically prescribed an intramuscular opioid on a "prn" basis until oral analgesia is appropriate.
Since Serturner first isolated morphine from opium almost 200 years ago, it has proved a valuable and versatile analgesic, being administered by a variety of routes. Typically in the postoperative setting morphine is given by intravenous (IV) or intramuscular (IM) injection. IM injections are unpleasant and have potential adverse effects including nerve damage and haematoma formation. They increase the risk of needle-stick injury to nursing staff and require expensive disposal mechanisms. Intravenous morphine is also effective but there is often a reluctance on the part of nursing staff to administer intravenous opioids in general postoperative wards.
In recent times there has been considerable interest in the subcutaneous route. A subcutaneous port such as a winged infusion needle or cannula can be inserted while the patient is under anaesthesia. Bolus dose or infusions can then be administered via this port, thus avoiding further injections to the patient and potential needle-stick injuries to staff. This technique avoids many of the disadvantages of IM or IV injection.
Subcutaneous morphine infusion has been shown to have great efficacy in the treatment of chronic malignant pain with a high patient acceptability and low side-effect profile [4] [5] [6] . Continuous subcutaneous infusions of morphine have been shown to provide simple and relatively effective postoperative analgesia in adults 7 and children 8 and provide similar plasma morphine levels to intravenous infusions 9 . Subcutaneous patientcontrolled analgesia (PCA) in children is as effective as intravenous PCA and results in a lower dose requirement for opioids 10 . There is however little clinical data on the efficacy of subcutaneous boluses as opposed to infusions. A study conducted in children suggested good efficacy and acceptance 11 but the methodology of this study has been criticized 12 . The acute pain unit of a major Australian teaching hospital now routinely uses subcutaneous morphine boluses as first line analgesia in patients where PCA or epidural analgesia are not indicated 13, 14 . This study compares morphine administered by the subcutaneous and intramuscular routes with particular reference to speed of onset, depth and duration of analgesia, patient acceptability and side-effect profile.
METHOD
Approval for the study was obtained from the Regional Health Authority Ethics Committee. Patients over the age of 18 years undergoing surgery at the Gold Coast Hospital were invited to participate in the study if their anaesthetist decided that epidural or PCA were not indicated. Exclusion criteria were contraindications to morphine (e.g. allergy), alteration of morphine pharmacokinetics (e.g. liver or renal failure, opioid dependence), chronic airflow limitation or respiratory depression.
Informed consent was obtained at pre-anaesthetic assessment. Fifty-nine patients (36 females and 23 males) entered the trial. Average age was 50.4 years (range 24-78) and average weight was 72.6 kg (range 44-107). Surgery included laparoscopic cholecystectomy (22) , vaginal hysterectomy (9), hernia repair (8), mastectomy (5), colposuspension (3), minor orthopaedic procedures (10), appendicectomy (1) and lymph node biopsy (1).
Four patients were excluded because laparoscopic cholecystectomy was converted to an open procedure and it was decided that PCA was more appropriate. One was excluded due to procedural error. Several patients required no analgesia during study hours and were therefore excluded. A total of 39 injections were given.
The choice of anaesthetic technique including intraoperative opioids was at the discretion of the anaesthetist. Following induction a 25 gauge Travenol Miniset needle was inserted into the subcutaneous tissue in the infraclavicular region and a Baxter Interlink needleless injection port attached. A transparent adhesive dressing was used to secure the cannula which was then flushed with 0.5 ml normal saline. Cannula deadspace including injection port was 0.32 ml.
The subject's weight was measured and a morphine dose calculated, based on a dose of 0.15 mg/kg. If the subject required postoperative analgesia, two syringes (A and B) were prepared by the pharmacy department, one containing morphine 0.15 mg/kg diluted with normal saline to a total volume of 0.5 ml, the other containing normal saline 0.5 ml. The contents of syringe A were injected into the subcutaneous needle, followed by a 0.5 ml flush with normal saline. The contents of syringe B were administered by intramuscular injection into the anterior thigh using a 23 gauge needle. The investigator and patient were both blinded as to which syringe contained the morphine. Each patient's initial route was randomized by the pharmacy department, syringes for subsequent doses alternated so the patient would receive morphine by the other route. One investigator performed all injections to minimize operator bias.
Prior to administration of the morphine the patient's pain was rated using a linear analog (0-10) scale. Blood pressure was measured using a Datascope 2100 automated noninvasive blood pressure monitor. Arterial oxygen saturation and heart rate were measured using a Criticare Systems 504 pulse oximeter. Respiration rate was recorded. Degree of sedation was assessed using a scale of 0-4 and the patient asked to rate the presence of nausea on a scale of 0-4 (Table 1) .
Following administration of morphine the same parameters were recorded at 15 minutes and at 1, 2, 3 and 4 hours after the dose. The subcutaneous needle site was inspected at each visit for signs of inflammation or skin irritation.
Immediately after administration the patient was asked to rate a preference, a strong preference or no preference for one or other of the injections. One blinded investigator performed all assessment on all patients and the same equipment was used in order to reduce observer bias. 
RESULTS
Patients received between 0 and 3 injections on request during the 48 hours following surgery.
Student's t-test was used to compare IM and SC administration for each of the following parameters: pain score, respiratory rate, saturation, heart rate and mean arterial pressure. There were no significant differences in any of these parameters at any of the review periods (Figures 1 to 5) .
The graphs show results at time 0, at 15 minutes after injection and at 1, 2, 3 and 4 hours after injection. In each case, subcutaneous injections (n=19) are shown as diamonds and intramuscular injections (n=20) as squares. Error bars indicate standard error of the mean.
Pain scores at each review period were compared to the score given before the injection. There was no significant difference between IM and SC morphine. The pain scores dropped to approximately three to four "units" less than the initial score at one hour and persisted for four hours (Figure 1) .
Figures 2-5 show graphs for respiratory rate, arterial oxygen saturation, heart rate and mean arterial pressure and indicate no significant change after administration of morphine nor any difference between the routes of administration.
Sedation and nausea scores were analysed using the Wilcoxon Rank sum test 15 . The median score was 1 for both routes except for one hour after subcutaneous administration when the median score was 2; however, statistical significance was not reached at any of the review periods (r1=351, 376, 419, 379, 373, 373 respectively, P>0.1.
The median nausea score was zero at each review period. There was no significant difference between IM and SC administration at any of the review periods (r1=374, 358, 389, 402, 433, 396 respectively, P>0.1). Interestingly the nausea scores tended to drop rather than increase after administration of morphine. This trend was stronger with IM than SC injection but did not reach statistical significance.
Patient preference for the injection site was analysed using the Chi-squared distribution with Yates' correction. Sixty-four per cent of patients (n=26) expressed either a preference or a strong preference for the subcutaneous injection, 28% (n=10) had no preference while 8% (n=3) had a preference or strong preference for the intramuscular injection (χ 2 0.05(2).2 =16.68; P<0.001) (Figure 6 ). No patient complained of pain at the needle site while the needle was in situ.
One patient receiving subcutaneous morphine noted a marked flare and a mild itch around the subcutaneous needle which started about 15 minutes after injection and had resolved completely by one hour. There was no other case of pruritus and no evidence of inflammation at injection sites. One patient receiving intramuscular morphine was noted to have arterial oxygen desaturation due to obstructive sleep apnoea which had not previously been diagnosed but was apparent on retrospective history taking. There were no other cases of respiratory depression.
DISCUSSION
This study showed no significant difference in analgesia when IM and SC boluses of morphine were compared. There were no differences in heart rate, mean arterial pressure, respiratory rate, arterial oxygen saturation, sedation or nausea scores.
The dose of 0.15 mg/kg was chosen so that morphine dose could be standardized between patients, although there is evidence of poor correlation between patient weight and opioid requirement 16 . An alternative is to base the dose on patient age 16 . The pain was assessed using a linear analog scale which has previously been described and validated 17 . Although clinical effects were the primary area of investigation the study may have been enhanced by correlating pain scores with a circulating level of morphine (or its glucuronides). Other investigators have shown that subcutaneous morphine infusions give the same circulating plasma levels as intravenous infusions 9 . Operator bias was avoided by having one blinded investigator perform all injections, and observer bias avoided by having one investigator perform all reviews and measurements using the same equipment. The sample purposefully included a range of operation types so that the findings would be more widely applicable. There was a high proportion of females, as expected from the nature of the surgery performed, but when gynaecological and breast procedures are excluded the gender distribution is equal.
This study showed that a statistically significant number of patients preferred the subcutaneous injection. The three patients who expressed a preference for IM injection had all received morphine by the subcutaneous route. Of those who expressed no preference, half received morphine subcutaneously and half by intramuscular injection. When analysing whether the route of morphine injection affected the patient preference, statistical significance was not reached. The subcutaneous needle was inserted under anaesthesia. If this had been inserted while the patient was awake then the preference may not be so strongly in favour of subcutaneous injection.
Possible disadvantages of subcutaneous administration include skin irritation 18 . This study showed only one case of minor and temporary irritation, a finding comparable with previous studies.
There has been a belief that absorption from the subcutaneous site would be too erratic and un- 12 but this has been repudiated by a study of the pharmacokinetics of subcutaneous administration in elderly patients 19 . Furthermore the pharmacokinetics of morphine by the subcutaneous route are known to be very similar to the intramuscular route 20 . Although studies have shown that opioid infusions give similar or better analgesia than intermittent boluses [21] [22] [23] , they carry added problems of requiring infusion equipment and the increased risk of administration error. They require a greater nursing workload and increased vigilance.
This study has shown good efficacy for a single bolus four hours after administration. An extendedrelease formulation of morphine for subcutaneous administration has been tested on animals and may be available in the future 24 . Pethidine can also be given by subcutaneous injection but appears to cause greater pain on injection 25 .
